[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"tachypnea\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:tachypnea":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,50],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100554740","phase-3-the-effect-of-phosphocreatine-on-medical-emergency-team-met-treated-patients-100554740",false,"NCT06503016","The Effect of phoSPHocreatine on mEdical Emergency Team (Met) tREated Patients","The Effect of phoSPHocreatine on mEdical Emergency Team (Met) tREated Patients: a Randomized Clinical Trial Protocol","SPHERE","Inclusion Criteria:\n\n1. Admitted in hospital (but outside ICU)\n2. Age\\>=18 years\n3. Written informed consent\n4. Serum creatinine \\\u003C=2 mg\u002Fdl\n5. Patient with impending or underlying cardiac failure or cardiac arrest, irrespectively of the primitive organ failure, and the Medical Emergency Team (MET) is called upon at least one of the following:\n\n   1. Threatened airways;\n   2. Respiratory arrest;\n   3. Respiratory rate \\\u003C5 or \\>36 breaths per min;\n   4. Pulse rate \\\u003C40 or \\>140 beats per min;\n   5. Systolic blood pressure \\\u003C 90 mm Hg;\n   6. Sudden fall in level of consciousness;\n   7. Fall in Glasgow coma scale of \\> 2 points.\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years;\n2. Ongoing cardiac massage;\n3. Current hospital admission from a care nursing facility;\n4. Planned discharge to a care nursing facility;\n5. Reasons for withdrawal of life-sustaining therapy;\n6. History of kidney transplantation;\n7. Solitary kidney (by any reason);\n8. Serum Creatinine \\> 2 mg\u002Fdl;\n9. Immediate need for ICU admission;\n10. Known allergy to PCr;\n11. Pregnancy;\n12. Previous enrollment and randomization into this trial;\n13. Administration of PCr in the previous 30 day.","ALL","18 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","Unexpected deaths and unplanned intensive care unit (ICU) admissions are common during hospital stay and are often preceded by warning abnormalities in patients' vital signs. These abnormalities trigger Medical Emergency Team (MET) activation and up to 15% of patients visited by the MET is admitted to the ICU with an overall hospital stay after the MET intervention of approximately 2 weeks. Phosphocreatine (PCr) is a natural energy-buffering molecule associated with signals of mortality reduction in patients with acute cardiac conditions (according to meta-analytic finding from our group) and with encouraging beneficial effects on other acute organ failures (e.g. brain). The investigators designed a multi-center, randomized, placebo-controlled trial to confirm the promising beneficial effects of PCr in hospitalized patients. The investigators expects a reduction in hospital stay (measured as an increase in days alive and out of hospital at 30 days) when PCr is added to standard treatment in patients requiring MET intervention.",[27,28,29,30,31,32,33,34,35,36],"Hypotension","Consciousness, Level Altered","Airway Disease","Respiratory Failure","Tachypnea","Bradypnea","Tachycardia","Bradycardia","Cardiac Failure","Cardiac Arrest","RECRUITING","2025-08-05",{"date":40,"type":41},"2025-08-06","ACTUAL",{"date":43,"type":41},"2024-10-08",{"date":45,"type":21},"2026-07",{"name":47,"class":48},"Università Vita-Salute San Raffaele","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":17,"minAge":18,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":69,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":5},"100508869","diaphragm-dysfunction-and-ultrasound-perioperatively-100508869","NCT05906030","Diaphragm Dysfunction and Ultrasound Perioperatively","Diaphragm Dysfunction and Respiratory Complications in the Perioperative Setting- Can Diaphragm Ultrasound Aid Prediction?","DiaphPeriop","Inclusion Criteria:\n\nAdults undergoing elective (study 1) or acute (study 2) abdominal, pelvic or vascular surgery\n\nExclusion Criteria:\n\n* \\\u003C18 years\n* Underlying chronic respiratory disease\n* Patients not able to give informed consent",true,"100 Years",{"count":61,"type":21},160,"OBSERVATIONAL","This study aims at determining whether diaphragm ultrasound examining diaphragm thickening fraction, excursion and density before and after surgery can predict respiratory complications in the postoperative period.\n\nPatients scheduled for major elective abdominal, pelvic or vascular surgery will be included in the study and diaphragm ultrasound is performed before surgery and after surgery in the postoperative ward. Physiological parameters, laboratory parameters, data on surgery and anesthesia and comorbidities will be registered. Complications such as pneumonia, desaturation, need for intubation and other respiratory events up to 30 days will be registered and later correlated with the diaphragm measurements.",[65,66,67,31,68],"Respiratory Insufficiency","Pneumonia","Desaturation of Blood","Atelectasis, Postoperative",[70,71,72,66,73],"Diaphragm dysfunction","Postoperative complication","Respiratory complication","Respiratory insufficiency","2025-01-27",{"date":76,"type":41},"2025-01-29",{"date":78,"type":41},"2024-09-01",{"date":80,"type":21},"2027-09-01",{"name":82,"class":48},"Karolinska University Hospital"]